|
|
 |
|
Viewing report
|
|
|
|
Generic Cancer Market - New Legislation and a Wave of Patent Expiries to Transform the Market
Datamonitor, Dec 2005, Pages: 179
Over the next 10 years a significant number of key oncology products, some with blockbuster status, will lose patent protection, thus exposing billions of dollars to generic erosion. While obviously a major threat to the key pharmaceutical players and sales of their branded products, this presents significant opportunities to potential generic manufacturers.
Scope of this title:
- Overview of the current generic cancer market, including profiles of key products and events impacting each during 200414
- Assessment of current and future opportunities and threats in the generic cancer market across the seven major pharmaceutical markets
- Individual country, EU5 and seven-market sales forecasts from 2004 to 2014 for branded products and their generic counterparts
- Detailed discussion of key strategic issues in the generic cancer market, plus three commercial impact and lifecycle management case studies
Highlights of this title:
The generic cancer market was worth $1.3 billion in 2004, and is set to grow at a CAGR of 24.3% to reach $10.9 billion by 2014. All classes of drugs are set to enjoy significant growth, although in some cases this is highly dependent on finalization and implementation of an explicit regulatory framework for the approval of biogenerics.
The cytotoxics and antihormonal therapy classes already suffer a high level of genericization, therefore further growth will arise via the patent expiration of existing newer products, some of which currently achieve, or are forecast to achieve, blockbuster sales of over $1 billion a year by 2014.
The targeted therapies and supportive care products offer perhaps the greatest opportunities for generic players, given their potential for blockbuster sales and key roles in cancer management. However, potential players in these markets must be prepared to wait for the relevant biogeneric legislation to be passed.
Reasons to order your copy:
- Understand market specific drivers and predict the future potential of key generic cancer therapies
- Assess the impact of patent expiries on key brand name products and identify the opportunities and risks for generic drugs in the seven major markets
- Adopt knowledge to drive strategic planning for generic products and optimize market penetration of new entrants
Customers who bought this item also bought
Commercial Insight: Antihormonal Cancer Therapies
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Injectable Generic Drugs: Prospects & Opportunities to 2013
Pipeline/Commercial Insight: Supportive Care In Oncology - Significant Growth Opportunities Exist In New Supportive Care Indications
Cancer Therapies - Global Market Opportunities
Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
Antihormonal Therapy Cancer Brands - Careful Lifecycle Management Needed to Preserve Brand Dominance
Commercial Insight: Cytotoxics - Generic Adversity Facing Major Cytotoxics
Cancer Therapies - Global Strategic Business Report
Antihormonal Therapies Market Forecast
Commercial Insight: Migraine - Opportunities will Exist in the Wake of Generic Attack
|
|
|
|
